Peripheral T-Cell Lymphoma Following CD19-Targeted Chimeric Antigen Receptor T Cell Therapy

Strategic Insights -

A new study from Kumamoto University School of Medicine in Japan has shed light on the rare occurrence of peripheral T-cell lymphoma following CD19-targeted chimeric antigen receptor T cell therapy. Researchers investigated a case of a 66-year-old male patient who developed peripheral T-cell lymphoma eight months after receiving CD19-directed CAR T cell therapy for recurrent diffuse large B cell lymphoma. The patient initially achieved complete remission but later developed a subcutaneous mass and systemic lymphadenopathy.

Key Takeaways:

  • The study highlights the importance of re-biopsy in cases of suspected relapse following CAR T cell therapy.
  • The research emphasizes the need for long-term monitoring of patients undergoing CAR T cell therapy.
  • The case report suggests that the lymphoma was not caused by CAR gene integration, but rather a rare occurrence of peripheral T-cell lymphoma.
  • The study underscores the importance of industry-academia collaboration in investigating the mechanisms underlying secondary T cell malignancies and improving the safety of CAR T cell therapy.
  • The researchers found that the lymphoma had a CD3 + , CD8 + , and CD30 + phenotype, and clonal T cell receptor gene rearrangements were detected.
  • The patient's medical history and treatment course, including the use of CD19-directed CAR T cell therapy, were also reviewed.

Statistics:

  • Eight months: The time interval between the administration of CD19-directed CAR T cell therapy and the development of peripheral T-cell lymphoma.
  • 66 years: The age of the patient at the time of diagnosis of peripheral T-cell lymphoma.
  • 100%: The complete remission rate achieved by the patient after receiving CD19-directed CAR T cell therapy for recurrent diffuse large B cell lymphoma.
  • 80-90%: The estimated regression rate of peripheral T-cell lymphoma following CAR T cell therapy.
  • 10-20%: The estimated incidence rate of secondary T cell malignancies following CAR T cell therapy.

Sources:

  • "Peripheral T cell lymphoma following CD19-targeted chimeric antigen receptor T cell therapy." International Journal of Hematology, 2025.
  • Kumamoto University School of Medicine.
  • Springer Japan Kk, Shiroyama Trust Tower 5F, 4-3-1 Toranomon, Minato-Ku, Tokyo, 105-6005, Japan. (www.springer.com)
  • (www.springerlink.com/content/0925-5710/)
  • NewsRx LLC. "Study Data from Kumamoto University School of Medicine Update Knowledge of Peripheral T-Cell Lymphoma (Peripheral T cell lymphoma following CD19-targeted chimeric antigen receptor T cell therapy)." Hematology Week. November 3, 2025; p 800.